Plain-English translation of NCT07332247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a newer approach to treating nasopharyngeal cancer (a type of throat cancer) that has come back after previous treatment. You would receive an immune-boosting medication called a PD-1 inhibitor to help your body fight the cancer. The main question is whether you should receive radiation therapy right away alongside this medication, or whether doctors should wait and only give radiation if the cancer grows in specific areas.
About 10-15% of people with this type of throat cancer experience it coming back after their first treatment, which is very difficult to treat. Doctors know that the medication works well when combined with chemotherapy, but they're uncertain whether adding radiation therapy on top helps patients live longer or causes too many side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups will receive the PD-1 inhibitor medication by IV infusion every three weeks for up to 2 years. One group will receive radiation therapy right away, while the other group will receive radiation only if their cancer starts growing in the neck or throat area. You will have regular clinic visits and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
China